Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Xpovio
Selinexor is a first-in-class, selective inhibitor of nuclear export compound (SINE) indicated for the treatment of certain hematologic malignancies. It works by blocking the exportin 1 (XPO1) protein, which is responsible for transporting tumor suppressor proteins and growth regulatory proteins out of the cell nucleus. By inhibiting XPO1, selinexor forces these proteins to remain in the nucleus where they can exert their anti-cancer effects. Selinexor is typically used in combination with other anti-cancer agents.
Selinexor is used to treat certain types of multiple myeloma and diffuse large B-cell lymphoma.
Selinexor has a Black Box Warning for severe or life-threatening thrombocytopenia (low platelet count). It can also cause other serious side effects such as nausea, vomiting, diarrhea, fatigue, anorexia, low levels of white blood cells and red blood cells, and increased risk of infection.
Outcome:
Increased selinexor levels
Mechanism:
Inhibition of CYP3A4
Outcome:
Increased selinexor levels
Mechanism:
Inhibition of CYP3A4
Outcome:
Decreased selinexor absorption
Mechanism:
Chelation
Most likely new formulation: Oral suspension (Year 2025, 60% confidence)
Based on current usage trends and clinical trial data, there is a 70% likelihood of expanded indications for selinexor in other hematologic malignancies within the next 5 years.
Antineoplastic Agent, Selective Inhibitor of Nuclear Export (SINE)
Selective Inhibitor of Nuclear Export